Featured Image for Epygenix Therapeutics
First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome
June 01, 2022 04:00 ET | Epygenix Therapeutics
PARAMUS, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focusedĀ on genetically screening, discovering and developingĀ safe, effective and...
Featured Image for Epygenix Therapeutics
Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer
May 23, 2022 04:00 ET | Epygenix Therapeutics
PARAMUS, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable...